Antimicrobial Resistance Diagnostics Market Size

Antimicrobial Resistance Diagnostics Market Size

The global antimicrobial resistance diagnostics market was valued at USD 4.4 billion in 2023 and is estimated to grow at a CAGR of over 6.3% from 2024 to 2032. The global market for diagnosing antimicrobial resistance is rapidly expanding because of the spread of antibiotic-resistant infections, the growing need for precision medicine, and increasing advancement in diagnostics technology.

For instance, according to the CDC, 2.8 million people in the U.S. afflicted with antibiotic-resistant infections, leading to over 36,500 deaths each year. The rising threat from these numbers increasing the demand for effective diagnostics to monitor infections leading to market growth.
 

The development of molecular diagnostics, immunoassays, and next-generation sequencing (NGS) have considerably heightened the accuracy and pace at which resistance is detected and diagnosed. For example, molecular diagnostics' accuracy makes them widely popular and readily accepted. In addition, antimicrobial resistance (AMR) has steadily emerged as an important area of concern for governments and health organizations globally, which subsequently leads to funding and efforts to improve diagnostic detection. In the U.S., for example, the National Action Plan combating antibiotic-resistant bacteria focuses on the need for rapid diagnostic testing.
 

AMR poses the most considerable threat to treatment and prevention against a constantly expanding spectrum of infections from bacteria, parasites, viruses, and fungi. Tests done quickly on sites of infections do not only help in identifying the presence of antimicrobial-resistant bacteria, assessing its susceptibility, and differentiating between viral or bacterial infections. They also help in effective treatment and in epidemiological surveillance because emerging resistant infective agents and their transmission can be tracked.